

# Publications for Michael Millward

## 2015

Blinman, P., Hughes, B., Crombie, C., Christmas, T., Hudson, M., Veillard, A., Muljadi, N., Millward, M., Wright, G., Flynn, P., Stockler, M., et al (2015). Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile? *European Journal of Cancer*, 51(12), 1529-1537. <a href="http://dx.doi.org/10.1016/j.ejca.2015.05.022">[More Information]</a>

## 2013

Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. *Lung Cancer*, 81(3), 422-427. <a href="http://dx.doi.org/10.1016/j.lungcan.2013.05.006">[More Information]</a>

Kim, K., Kefford, R., Pavlick, A., Infante, J., Ribas, A., Sosman, J., Fecher, L., Millward, M., McArthur, G., Hwu, P., Long, G., et al (2013). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. *Journal of Clinical Oncology*, 31(4), 482-489. <a href="http://dx.doi.org/10.1200/JCO.2012.43.5966">[More Information]</a>

Nathanson, K., Martin, A., Wubbenhorst, B., Greshock, J., Letrero, R., D'Andrea, K., O'Day, S., Infante, J., Falchook, G., Arkenau, H., Kefford, R., Long, G., et al (2013). Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). *Clinical Cancer Research*, 19(17), 4868-4878. <a href="http://dx.doi.org/10.1158/1078-0432.CCR-13-0827">[More Information]</a>

## 2012

Boyer, M., Horwood, K., Pavlakakis, N., de Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012). Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. *Asia-Pacific Journal of Clinical Oncology*, 8(3), 248-254. <a href="http://dx.doi.org/10.1111/j.1743-7563.2012.01540.x">[More Information]</a>

## 2006

Soo, R., Wang, L., Tham, L., Yong, W., Boyer, M., Lee, H., Lim, H., Millward, M., Liang, S., Beale, P., et al (2006). A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. *Annals of Oncology*, 17(7), 1128-1133. <a href="http://dx.doi.org/10.1093/annonc/mdl084">[More Information]</a>

Kefford, R., Beith, J., Van Hazel, G., Millward, M., Trotter, J., Wyld, D., Kusic, R., Shreeniwas, R., Morganti, A., Ballmer, A., et al (2006). A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. *Investigational New Drugs*, 25(3), 247-252. <a href="http://dx.doi.org/10.1007/s10637-006-9014-7">[More Information]</a>

</a></p></div>
<div data-bbox="506 136 952 242" data-label="Text">
<p>Bedikian, A., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A., DeConti, R., Hersh, E., Hersey, P., et al (2006). Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group. *Journal of Clinical Oncology*, 24(29), 4738-4745. <a href="http://dx.doi.org/10.1200/JCO.2006.06.0483">[More Information]</a></p></div>
<div data-bbox="506 249 955 328" data-label="Text">
<p>Francken, A., Fulham, M., Millward, M., Thompson, J. (2006). Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. *European Journal of Surgical Oncology*, 32(7), 780-784. <a href="http://dx.doi.org/10.1016/j.ejso.2006.04.011">[More Information]</a></p></div>
<div data-bbox="506 334 956 415" data-label="Text">
<p>Kirkwood, J., Kefford, R., Logan, T., Mainwaring, P., Millward, M., Pavlick, A., Dar, M., Kathman, S., Laubscher, K., Bell, W. (2006). Phase II trial of ibotectedin (rhIL-18) on a daily X 5 schedule in metastatic melanoma (MM). *2006 American Society of Clinical Oncology (ASCO) Annual Meeting*, United States: American Society of Clinical Oncology.</p></div>
<div data-bbox="506 421 943 514" data-label="Text">
<p>Kohonen-Corish, M., Cooper, W., Saab, J., Thompson, J., Trent, R., Millward, M. (2006). Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. *Journal of Investigative Dermatology*, 126(1), 167-171. <a href="http://dx.doi.org/10.1038/sj.jid.5700005">[More Information]</a></p></div>
<div data-bbox="506 522 565 540" data-label="Section-Header">
<h2>2005</h2></div>
<div data-bbox="506 547 952 640" data-label="Text">
<p>Francken, A., Hong, A., Fulham, M., Millward, M., McCarthy, W., Thompson, J. (2005). Detection of unsuspected spinal cord compression in melanoma patients by 18F-fluorodeoxyglucose-positron emission tomography. *European Journal of Surgical Oncology*, 31(2), 197-204. <a href="http://dx.doi.org/10.1016/j.ejso.2004.08.009">[More Information]</a></p></div>
<div data-bbox="506 646 912 714" data-label="Text">
<p>Sharma, R., Boyer, M., Clarke, S., Millward, M. (2005). Gefitinib in advanced non-small cell lung cancer. *Internal Medicine Journal*, 35(2), 77-82. <a href="http://dx.doi.org/10.1111/j.1445-5994.2005.00776.x">[More Information]</a></p></div>
<div data-bbox="506 720 952 813" data-label="Text">
<p>Millward, M., Joshua, A., Kefford, R., Aamdal, S., Thomson, D., Hersey, P., Toner, G., Lynch, K. (2005). Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. *Investigational New Drugs*, 23(3), 253-256. <a href="http://dx.doi.org/10.1007/s10637-005-6734-z">[More Information]</a></p></div>
<div data-bbox="506 818 936 926" data-label="Text">
<p>Chan, A., Hsu, M., Goh, B., Hui, E., Liu, T., Millward, M., Hong, R., Whang-Peng, J., Ma, B., To, K., et al (2005). Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. *Journal of Clinical Oncology*, 23(15), 3568-3576. <a href="http://dx.doi.org/10.1200/JCO.2005.02.147">[More Information]</a></p></div>
<div data-bbox="506 933 565 952" data-label="Section-Header">
<h2>2003</h2></div>
</html>

Millward, M., Boyer, M., Lehnert, M., Clarke, S., Rischin, D., Goh, B., Wong, J., McNeil, E., Bishop, J. (2003). Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. *Annals of Oncology*, 14(3), 449-454. <a href="http://dx.doi.org/10.1093/annonc/mdg118">[More Information]</a>

## 2002

Rischin, D., Ackland, S., Smith, J., Garg, M., Clarke, S., Millward, M., Toner, G., Zalcberg, J. (2002). Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies. *Annals of Oncology*, 13(11), 1810-1818. <a href="http://dx.doi.org/10.1093/annonc/mdf305">[More Information]</a>

Clarke, S., Abratt, R., Goedhals, L., Boyer, M., Millward, M., Ackland, S. (2002). Phase II trial of pemetrexed disodium (ALIMTA[R], LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. *Annals of Oncology*, 13(5), 737-741. <a href="http://dx.doi.org/10.1093/annonc/mdf115">[More Information]</a>

## 2000

Rischin, D., Boyer, M., Smith, J., Millward, M., Michael, M., Bishop, J., Zalcberg, J., Davison, J., Emmett, E., McClure, B. (2000). A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. *Annals of Oncology*, 11, 421-426.

Rischin, D., Smith, J., Millward, M., Lewis, C., Richardson, G., Boyer, M., Toner, G., Gurney, H., McKendrick, J. (2000). A phase II trial of paclitaxel and epirubicin in advanced breast cancer. *British Journal of Cancer*, 83(4), 438-442.

Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. *Clinical Cancer Research*, 6, 3480-3485.